The FDA announced it will be reducing, refining and potentially replacing the animal testing requirement for the approval of ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

On Friday, U.S. Sen. Rand Paul, R-Bowling Green, was joined by three colleagues in reintroducing bipartisan legislation to ...